查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718315

抗风湿药物市场按药物类别、给药途径、类型、疾病类型和分销管道划分－2025-2030 年全球预测

Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗风湿药物市场预计2023年将达到915.4亿美元，2024年将达到965.6亿美元，到2030年将达到1,347.7亿美元，复合年增长率为5.68%。

主要市场统计数据
基准年2023年 915.4亿美元
预计2024年 965.6亿美元
预测年份 2030 1347.7亿美元
复合年增长率（%） 5.68%

全球抗风湿药物市场正在经历显着变革，需要深入了解不断发展的治疗模式。近年来，相关人员见证了治疗方法的空前进步，推动了各个领域稳定而有希望的成长。本报告提供了深入的分析，不仅反映了当前的行业指标，还预测了未来的挑战和机会。不断增长的患者需求加上创新的研究和开发正在推动市场相关人员重新评估传统治疗策略并采用新的治疗方法。医疗保健环境的动态特性促进了合作和竞争的精神，从而显着改善了患者的治疗效果并增强了产品平臺。此外，全球政策和监管改革也在不断发展，简化了加速产品核可和增强市场信心的途径。该研究利用强大的数据分析和先进的数位工具，提供了对决策者和行业专业人士至关重要的全面观点。本简报是了解风湿病市场复杂性的入门读物，也是深入研究关键产业趋势和竞争策略的基础。

改变抗风湿药物市场

近年来，抗风湿药物市场发生了转变，将自己定位在医疗创新和患者照护的前沿。该行业已经出现了大量先进的研究方法，从而可以开发标靶治疗和个性化的治疗方法。这些创新是由生物技术的进步和对风湿病病理病理学的更深入理解所推动的。法律规范也发生了重大变化，一些地区的主管部门加快了核准流程，使突破性治疗方法能够更快地进入市场。合资企业和策略伙伴关係增强了研究和开发，使得针对特定发炎途径的新型药物得到广泛应用。此外，人们特别关注数位健康和​​数据分析的应用，这可以改善诊断和病患监测，并最终改善治疗结果。随着患者寻求更有效、更安全的替代医疗方法，该行业迅速做出反应，将最尖端科技融入传统医疗模式。这种适应性方法不仅使其产品多样化，而且增强了其市场竞争力。发展趋势表明，技术与药物开发的融合将继续成为抗风湿药物市场成功的关键决定因素。

风湿病市场的详细細項分析

详细的市场細項分析揭示了抗风湿药物市场的复杂性，突显了推动患者照护和商业性成功的多维因素。市场按药物类别细分，包括对皮质类固醇、缓解疾病的抗风湿药物、非类固醇消炎剂和尿酸药物的详细研究。在缓解疾病的抗风湿药物领域中特别值得注意的是它细分为生物製剂 DMARD、常规 DMARD 和标靶合成 DMARD。基于 B 细胞抑制剂、白细胞介素抑制剂、T 细胞共刺激调节剂和肿瘤坏死因子 (TNF) 抑制剂进一步探讨生物 DMARD 的每个部分，以阐明其具体的作用机制和治疗细微差别。此外，该分析还扩展到给药途径，了解注射、口服和局部製剂的动力学，有助于将患者偏好与临床疗效相匹配。按产品类型细分，区分非处方药和处方药，以符合法规要求和市场进入。疾病类型透过考虑僵直性脊椎炎、黏液囊炎、痛风、幼年特发性关节炎、骨关节炎、干癣性关节炎类风湿性关节炎、修格兰氏症候群、系统性红斑狼疮、全身性红斑性狼疮硬皮症/硬皮症和肌腱炎等疾病进一步细分市场研究。最后一层细分考虑分销管道，重点关注医院药房、线上药房和零售药房，这些管道在这些治疗的可用性和商业化中发挥关键作用。这种全面的细分提供了市场的详细全景，并为相关人员提供了未来商业机会所在的策略见解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 风湿病患病率不断上升
      • 提高对类风湿性关节炎早期筛检和治疗的认识
      • 专注于精准医疗和个人化医疗
    • 限制因素
      • 抗风湿药物的副作用与安全问题
    • 机会
      • 政府对风湿病研究与发展的倡议与支持
      • 具有成本效益的生物相似药的关键开发和分销
    • 任务
      • 复杂的药物研发与核准流程
  • 市场区隔分析
    • 药物类别：非类固醇消炎剂因其可用性、可负担性和有效的疼痛管理而日益普及
    • 给药途径：口服药物製剂的进步可提高生物有效性并最大程度减少副作用
    • 类型：严重和慢性风湿病的治疗首选处方药
    • 疾病类型：类风湿性关节炎个人化医疗的进展，以优化疗效并最大限度地减少副作用
    • 分销管道：扩大抗风湿药物的网路药局分销
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗风湿药物市场（依药物类别）

  • 介绍
  • 皮质类固醇
  • 缓解疾病的抗风湿药物
    • 生物药物
      • B细胞抑制剂
      • 白细胞介素抑制剂
      • T细胞共刺激调节剂
      • 肿瘤坏死因子（TNF）抑制剂
    • 传统 DMARD 药物
    • 标靶合成DMARD
  • 非类固醇消炎剂
  • 尿酸药物

第七章抗风湿药物市场（依给药途径）

  • 介绍
  • 注射
  • 口服
  • 局部的

第八章抗风湿药物市场（按类型）

  • 介绍
  • 非处方药
  • 处方药

第九章抗风湿药物市场（依疾病型态）

  • 介绍
  • 僵直性脊椎炎
  • 黏液囊炎
  • 痛风
  • 幼年特发性关节炎
  • 骨关节炎
  • 骨质疏鬆症
  • 多肌痛
  • 干癣性关节炎
  • 类风湿性关节炎
  • 修格兰氏症候群
  • 全身性红斑性狼疮
  • 系统性硬皮症
  • 肌腱炎

第十章抗风湿药物市场（依通路）

  • 介绍
  • 医院药房
  • 网路药局
  • 零售药局

第 11 章：美洲抗风湿药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12.亚太抗风湿药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13.欧洲、中东和非洲抗风湿药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • DeepCure
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ILTOO Pharma SAS
  • Johnson & Johnson Services Inc.
  • medac GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market was valued at USD 91.54 billion in 2023 and is projected to grow to USD 96.56 billion in 2024, with a CAGR of 5.68%, reaching USD 134.77 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 91.54 billion
Estimated Year [2024] USD 96.56 billion
Forecast Year [2030] USD 134.77 billion
CAGR (%) 5.68%

The global market for anti-rheumatics is undergoing an era of notable change that calls for a deep understanding of the evolving therapeutic landscape. In recent years, stakeholders have observed unprecedented advancements in treatment modalities, driving a steady and promising growth in various segments. This report introduces a detailed analysis that not only reflects current industry metrics but also anticipates future challenges and opportunities. Over time, increasing patient demand paired with innovative research and development has encouraged market players to reevaluate conventional treatment strategies and embrace novel therapeutic approaches. The dynamic nature of the healthcare environment has fostered a spirit of collaboration and competition, leading to significant improvements in patient outcomes and enhanced product pipelines. Furthermore, evolving global policies and regulatory reforms have streamlined pathways for faster product approvals and heightened market confidence. Leveraging robust data analytics and advanced digital tools, the study presents a comprehensive view that is essential for decision-makers and industry experts. This briefing serves as a primer to understand the complexities of the anti-rheumatics market, setting the stage for a detailed exploration of key industry trends and competitive strategies.

Transformative Shifts in the Anti-Rheumatics Market Landscape

Recent years have witnessed transformative shifts that have reshaped the anti-rheumatics market, positioning it at the frontier of medical innovation and patient care. The industry has experienced a surge in advanced research methodologies, enabling the development of targeted treatments and personalized therapies. These innovations have been driven by improvements in biotechnology and a deeper understanding of the pathophysiology of rheumatic diseases. A significant shift has been observed in the regulatory framework where authorities across several regions have expedited the approval processes, resulting in quicker market access for groundbreaking therapies. Collaborative ventures and strategic partnerships have bolstered research and development, leading to a proliferation of novel agents that target specific inflammatory pathways. Additionally, there has been a pronounced focus on embracing digital health and data analytics, which has improved diagnostics and patient monitoring, ultimately enhancing therapeutic outcomes. As patients demand more effective and safer alternatives, the industry has responded rapidly by integrating state-of-the-art technologies with traditional healthcare models. This adaptive approach has not only diversified the product offerings but has also strengthened market competitiveness. Emerging trends indicate that the convergence of technology with pharmaceutical development will continue to be a critical determinant of success in the anti-rheumatics market.

In-Depth Segmentation Insights Across the Anti-Rheumatics Market

A detailed segmentation analysis reveals the intricacies of the anti-rheumatics market and underscores the multi-dimensional factors driving patient care and commercial success. The market is categorized based on drug class, which includes an in-depth study of Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. Particularly noteworthy within the Disease Modifying Anti-rheumatics Drugs segment is the subdivision into Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. Each segment within the Biologic DMARDs is further examined based on B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors, offering clarity on specific mechanisms of action and therapeutic nuances. Additionally, the analysis extends to the route of administration, capturing the dynamics of Injectable, Oral, and Topical formulations, which serve to match patient preference with clinical effectiveness. Segmentation based on product type distinguishes Over-the-Counter from Prescription-Based Drugs, thereby aligning regulatory requirements with market access. Disease type further refines the market study by considering conditions including Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis. The final layer of segmentation examines distribution channels, highlighting Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which play a critical role in the accessibility and commercialization of these therapies. This comprehensive segmentation captures the detailed panorama of the market, offering stakeholders strategic insights into where future opportunities lie.

Based on Drug Class, market is studied across Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. The Disease Modifying Anti-rheumatics Drugs is further studied across Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. The Biologic DMARDs is further studied across B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors.

Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.

Based on Type, market is studied across Over-the-Counter Drugs and Prescription-Based Drugs.

Based on Disease Type, market is studied across Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Navigating Global Opportunities in Anti-Rheumatics

Regional dynamics play a pivotal role in shaping the future trajectory of the anti-rheumatics market, and a nuanced understanding of geographical trends is essential. In the Americas, robust healthcare infrastructure and proactive policy measures have propelled the adoption of advanced therapies. The region presents lucrative opportunities anchored by high awareness, substantial investment in research, and progressive regulatory frameworks. Europe, Middle East & Africa is witnessing significant transformations with a focus on integrating traditional treatment models with novel therapeutic approaches. Stakeholders in this diverse region are increasingly examining the balance between cost-effectiveness and scientific innovation, paving the way for breakthrough approvals and enhanced patient outcomes. The Asia-Pacific region stands out due to its dynamic economic growth and rising middle-class populations that are driving an increased demand for quality healthcare services. Rapid urbanization, coupled with government initiatives to enhance healthcare access, has created a fertile ground for market expansion. By evaluating these regional insights, industry leaders can better strategize product positioning and market penetration, taking into account local regulatory landscapes, cultural nuances, and economic factors that influence patient care and adoption rates.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Leading Companies in the Anti-Rheumatics Sector

The competitive landscape within the anti-rheumatics market is characterized by the presence of several key companies that are spearheading innovation and market expansion. Prominent entities such as AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., and AstraZeneca PLC are at the forefront of developing and commercializing advanced therapies. Esteemed organizations like Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, and C. H. Boehringer Sohn AG & Co. KG have consistently demonstrated excellence in clinical research and development. Emerging innovators including DeepCure and Eisai Co., Ltd. are also making significant inroads with specialized treatment offerings. Industry giants like Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG continue to leverage extensive research networks to drive product innovation. In addition, organizations such as Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, and ILTOO Pharma SAS provide crucial insights into market strategies and emerging trends. Well-established names including Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., and Novartis AG underscore the market's competitive intensity. Not to be overlooked are companies like Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated, whose collaborative efforts continue to redefine therapeutic standards in the field. Their strategic initiatives not only drive competitive advancements but also significantly impact the overall market dynamics.

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, DeepCure, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, ILTOO Pharma SAS, Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., Novartis AG, Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated. Actionable Recommendations for Strategic Market Leadership

Industry leaders are encouraged to adopt a multifaceted approach to harness the full potential of the anti-rheumatics market. To remain competitive, it is essential to invest in robust R&D capabilities that focus on precision medicine and personalized therapies, ensuring that treatment options are tailored to individual patient needs. Expanding product portfolios across diverse drug classes and routes of administration can effectively address varying patient demographics and preferences. Leaders should also explore strategic partnerships and collaborations to accelerate innovation and expand market access, particularly in emerging economies where healthcare infrastructure is rapidly evolving. An emphasis on data-driven insights will enable decision-makers to identify untapped market segments and optimize distribution channels, including hospital, online, and retail pharmacies. Furthermore, leveraging digital technologies such as AI and machine learning can streamline clinical trials and enhance patient engagement. Regulatory compliance must remain at the forefront of any strategic initiative, with a proactive approach to meet evolving global standards. By embracing these recommendations, companies can not only mitigate market risks but also capitalize on emerging trends, ultimately driving sustainable growth and competitive differentiation in a constantly evolving healthcare landscape.

Conclusion: Synthesizing Insights for Future Growth

In summary, the anti-rheumatics market presents robust opportunities underpinned by transformative technological and regulatory advancements. The in-depth segmentation analysis, regional evaluations, and company performance insights collectively reinforce a narrative of dynamic growth and innovation. As the landscape continues to evolve with a focus on targeted therapies and patient-centric solutions, stakeholders are well-positioned to benefit from these changes by strategically aligning their business models with current market trends. This comprehensive summary encapsulates the critical areas that require focus and continued investment to ensure long-term success in the anti-rheumatics domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of rheumatic disorders
      • 5.1.1.2. Rise in awareness related to early screening and treatment of rheumatoid arthritis
      • 5.1.1.3. Growing emphasis on precision therapeutics and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects and safety issues associated with anti-rheumatic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives and support for the research and development of the rheumatic diseases
      • 5.1.3.2. Significant development and marketing of cost-effective biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. Complex drug development and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing adoption of nonsteroidal anti-inflammatory drugs due to their accessibility, affordability, and effective management of pain
    • 5.2.2. Route Of Administration: Advancements in oral drug formulations aiming to improve bioavailability and minimize adverse effects
    • 5.2.3. Type: Significant preference for prescription-based drugs in managing severe and chronic rheumatic diseases
    • 5.2.4. Disease Type: Evolving personalized medicine advancement in rheumatoid arthritis to optimize treatment outcomes and minimize side effects.
    • 5.2.5. Distribution Channel: Expanding online pharmacies for anti-rheumatic medication distribution
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Disease Modifying Anti-rheumatics Drugs
    • 6.3.1. Biologic DMARDs
      • 6.3.1.1. B-cell Inhibitors
      • 6.3.1.2. Interleukin Inhibitors
      • 6.3.1.3. T-cell Co-stimulation Modulators
      • 6.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
    • 6.3.2. Conventional DMARDs
    • 6.3.3. Targeted Synthetic DMARDs
  • 6.4. Nonsteroidal Anti-inflammatory Drugs
  • 6.5. Uric Acid Drugs

7. Anti-Rheumatics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Anti-Rheumatics Market, by Type

  • 8.1. Introduction
  • 8.2. Over-the-Counter Drugs
  • 8.3. Prescription-Based Drugs

9. Anti-Rheumatics Market, by Disease Type

  • 9.1. Introduction
  • 9.2. Ankylosing Spondylitis
  • 9.3. Bursitis
  • 9.4. Gout
  • 9.5. Juvenile Idiopathic Arthritis
  • 9.6. Osteoarthritis
  • 9.7. Osteoporosis
  • 9.8. Polymyalgia Rheumatica
  • 9.9. Psoriatic Arthritis
  • 9.10. Rheumatoid Arthritis
  • 9.11. Sjogren's Syndrome
  • 9.12. Systemic Lupus Erythematosus
  • 9.13. Systemic Sclerosis/Scleroderma
  • 9.14. Tendinitis

10. Anti-Rheumatics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Anti-Rheumatics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-Rheumatics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Rheumatics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Johnson & Johnson showcases advances in rheumatic disease treatments with 43 abstracts at ACR 2024
    • 14.3.2. FDA expands Shorla's JYLAMVO approval to combat pediatric oncology and autoimmune conditions
    • 14.3.3. DeepCure's DC-9476 methotrexate resistance in rheumatoid arthritis treatment
    • 14.3.4. FDA approval of Kevzara for treatment of pediatric and adult inflammatory arthritis
    • 14.3.5. Eisai and nippon medac launch Japan's first self-administered methotrexate pen
    • 14.3.6. Teva and Alvotech introduce SIMLANDI an interchangeable Humira biosimilar in the U.S.
    • 14.3.7. Kiniksa advances abiprubart in Phase 2b Trial for Sjogren's Disease, building on results from rheumatoid arthritis trial
    • 14.3.8. Fresenius Kabi's FDA approval of TYENNE tocilizumab biosimilar introduces in the anti-rheumatics market
    • 14.3.9. FDA approval revolutionizes rheumatic care with Novartis' Cosentyx
    • 14.3.10. Sandoz launches citrate-free high-concentration biosimilar Hyrimoz in the U.S. market
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. GlaxoSmithKline PLC
    • 14.4.2. Johnson & Johnson Services Inc.
    • 14.4.3. Novartis AG
    • 14.4.4. AbbVie Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alvotech
  • 3. Amgen Inc.
  • 4. ANI Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. C. H. Boehringer Sohn AG & Co. KG
  • 10. DeepCure
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. Galapagos NV
  • 16. Gilead Sciences, Inc.
  • 17. GlaxoSmithKline PLC
  • 18. ILTOO Pharma SAS
  • 19. Johnson & Johnson Services Inc.
  • 20. medac GmbH
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • 24. Pfizer, Inc.
  • 25. Regeneron Pharmaceuticals, Inc.
  • 26. Sanofi SA
  • 27. Takeda Pharmaceutical Company Limited
  • 28. Teva Pharmaceutical Industries Ltd.
  • 29. UCB S.A.
  • 30. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-RHEUMATICS MARKET MULTI-CURRENCY
  • FIGURE 2. ANTI-RHEUMATICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
  • FIGURE 4. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 318. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 319. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 320. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 332. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 333. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 334. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 337. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 338. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023